General Information

Click here to view the Conference Brochure

CONFERENCE FOCUS
The focus of HEP DART 2011 is to assemble clinicians, researchers and basic scientists together to advance our knowledge of the ongoing drug development processes in the treatment of hepatitis B and hepatitis C and other viruses affecting the liver, including co-infections with HIV.  HEP DART 2011 will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in therapeutics for hepatitis infection.

Continuing Medical Education
Accreditation Statement and Credit Designation Statement
Emory University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Emory University School of Medicine designates this educational activity for 27 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Conference Program Highlights
The conference program includes sessions covering the following topics:

• Global Burden of HBV/HCV, Natural History, and Therapeutic Management
• Discoveries and Advances in HCV Basic Research
• New Targets: Cellular Systems and Infectious Models
• New Targets: Insights into Drug Mechanisms
• Management of Hepatitis Infections
• Emergence and Prevention of Viral Resistance
• The Business of Antiviral Agents: Paying for Performance
• Clinical Trial Design
• Hepatitis B Foundation Symposium: Are New Drugs Needed to Prevent HBV?
• The Future of HCV Therapy in Non-genotype 1 Patients
• Pharmacology and New Therapies for Hepatitis Infections
• Co-infections, Therapeutic Modalities and Regulatory Issues
• Immunological Approaches and Vaccines for Hepatitis Infections
• Diagnostics, Liver Damage, Decompensation, Fibrosis and Hepatocellular Carcinoma

Conference Objectives
The Scientific Committee has designed the Conference program to ensure that the delegates achieve the following objectives:

• Understand the role of viral targets in the drug development and discovery process
• Identify the next generation of inhibitors of viral hepatitis
• Assess the impact of resistance and treatment failure in the drug development and discovery process
• Increase awareness of the clinical impact of antiviral agents
• Understand the consequences of co-infection with HIV on the management of patients
• Assess the role of vaccines and therapeutic vaccines in future therapies for viral hepatitis

Target Audience
The Conference is open to anyone interested in therapies for viral hepatitis. However, the content of this Conference was developed to primarily interest scientists and clinical researchers in the infectious diseases.